Compounders Research Compare

Rezolute, Inc.(RZLT)

Biotechnology · Redwood City, CA

$4.28-0.05 (-1.27%)

Delayed quote: Oct 6, 2026, 1:15 PM EDT

About Rezolute, Inc.

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Redwood City, CA

58 employees

www.rezolutebio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Nevan Charles Elam

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T17:18:03.602Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:18:03.602Z.

Quote observation: 2026-10-06T17:15:11.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 411,649,583
Total debt · period ending 2026-06-30: 934,000
Cash · period ending 2026-06-30: 10,615,000
TTM operating income · period ending 2026-06-30: -82,966,000

FMP input reference: eb6c183c54b52a3f5be7b88cd35f52a8db6123751fb387d2cb2c86d403628cdc

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

RZLT EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

RZLT Competitors' EV/EBIT Ratio

Rezolute, Inc.

Current

Market Cap

$411.65M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Prothena Corporation plc

Market Cap

$411.76M

EV/EBIT Ratio

N/A

TTM Avg

16.65x

3Y Avg

16.65x

5Y Avg

16.65x

Strata Critical Medical, Inc.

Market Cap

$410.19M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Shoulder Innovations, Inc.

Market Cap

$409.99M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Myriad Genetics, Inc.

Market Cap

$413.54M

EV/EBIT Ratio

N/A

TTM Avg

135.39x

3Y Avg

60.74x

5Y Avg

42.42x

Atea Pharmaceuticals, Inc.

Market Cap

$407.34M

EV/EBIT Ratio

N/A

TTM Avg

5.76x

3Y Avg

28.76x

5Y Avg

28.76x

Eikon Therapeutics, Inc. Common Stock

Market Cap

$403.87M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Neurogene Inc.

Market Cap

$406.04M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Senseonics Holdings, Inc.

Market Cap

$419.42M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Carlsmed, Inc.

Market Cap

$406.41M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Rezolute, Inc. (RZLT)	$411.65M	N/A	N/A	N/A	N/A
Prothena Corporation plc (PRTA)vs ›	$411.76M	N/A	16.65x	16.65x	16.65x
Strata Critical Medical, Inc. (SRTA)vs ›	$410.19M	N/A	N/A	N/A	N/A
Shoulder Innovations, Inc. (SI)vs ›	$409.99M	N/A	N/A	N/A	N/A
Myriad Genetics, Inc. (MYGN)vs ›	$413.54M	N/A	135.39x	60.74x	42.42x
Atea Pharmaceuticals, Inc. (AVIR)vs ›	$407.34M	N/A	5.76x	28.76x	28.76x
Eikon Therapeutics, Inc. Common Stock (EIKN)vs ›	$403.87M	N/A	N/A	N/A	N/A
Neurogene Inc. (NGNE)vs ›	$406.04M	N/A	N/A	N/A	N/A
Senseonics Holdings, Inc. (SENS)vs ›	$419.42M	N/A	N/A	N/A	N/A
Carlsmed, Inc. (CARL)vs ›	$406.41M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics